|Day Low/High||14.84 / 15.15|
|52 Wk Low/High||7.33 / 15.40|
New Research Expands Understanding of ZX008 Mechanism in Treating Seizures
Study 1 Top-Line Data on Track for 3Q 2017
Investors in Zogenix Inc. saw new options become available today, for the August 18th expiration.
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zogenix Inc. , where a total of 1,940 contracts have traded so far, representing approximately 194,000 underlying shares.
Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.
Issued Patent is First Covering Company's Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy
Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST
Shares of Omeros fell almost 10% after analysts' downgraded the biotech.